Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Daiichi Sankyo
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of Type 2 diabetes mellitus
Inadequate glycemic control on a stable dose (at least 2 months prior to screening) of pioglitazone at 30 or 45 mg/day, with or without one or two other oral antidiabetic medications \[metformin or a sulfonylurea, or dipeptidyl peptidase (DPP-IV) inhibitor\]
Hemoglobin A1c (HbA1c) \>= 7.5% and =\< 9.5% at screening
Fasting plasma glucose =\<240 mg/dL at randomization (Week 0/Day 1).
Male or female \>= 18 years of age.
Women of childbearing potential must be using an adequate method of contraception as detailed per-protocol
Fasting C-peptide level \>0.5 ng/mL at screening
Clinically stable in regards to medical conditions other than type 2 diabetes
Concomitant medications are at stable doses for at least 30 days prior to enrollment, and are not anticipated to need adjustment during the study period
You may not be if
History of Type 1 diabetes and/or history of ketoacidosis
History of bowel obstruction
History of hypertriglyceridemia-induced pancreatitis
History of dysphagia, swallowing disorders, gastroparesis, other gastrointestinal motility disorders, major gastrointestinal surgery
History of insulin use \>= 2 weeks duration during the previous 3 months or a total of \>2 months insulin therapy at any time prior to screening
Treatment with bile acid sequestrants, including colesevelam within 3 months prior to screening
Female subject who is pregnant or breastfeeding
History of unstable angina, myocardial infarction, cerebrovascular accident, transient ischemic attack, or any revascularization within 6 months prior to screening
